Skip to main content
Article
Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production
Dermatology Publications and Presentations
  • Kathryn J. Martires, Case Western Reserve University
  • Laura Capaldi, Roger Williams Medical Center
  • Sean F. Pattee, Dermatology Associates of Wisconsin
  • Mary E. Maloney, University of Massachusetts Medical School
  • Jeremy S. Bordeaux, Case Western Reserve University
UMMS Affiliation
Department of Medicine, Division of Dermatology
Date
9-1-2010
Document Type
Letter to the Editor
Medical Subject Headings
Administration, Topical; Aminoquinolines; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Immunohistochemistry; Melanoma, Amelanotic; Middle Aged; Neoplasm Recurrence, Local; Nose; Risk Assessment; Skin Neoplasms; Treatment Outcome
Abstract
A melanotic lentigo maligna (ALM) represents a small subset of lentigo maligna (LM) that lacks pigment. At least 2 cases of ALM responsive to imiquimod therapy with short-term follow-up have been reported. We report herein a case of ALM that failed to respond to imiquimod treatment. Furthermore, after therapy was initiated, the ALM began to produce pigment and transformed to LM.
Comments

Citation: Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol. 2010 Sep;146(9):1047-8. doi: 10.1001/archdermatol.2010.237.

Related Resources
Link to Article in PubMed
Citation Information
Kathryn J. Martires, Laura Capaldi, Sean F. Pattee, Mary E. Maloney, et al.. "Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production" Vol. 146 Iss. 9 (2010) ISSN: 0003-987X (Linking)
Available at: http://works.bepress.com/mary_maloney/26/